AKERO THERAPEUTICS, INC. - Common Stock (AKRO) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AKRO
Shares outstanding
82,872,659
Price per share
$40.63
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
20,018
Total reported value
$532,984
% of total 13F portfolios
0%
Share change
-91,333,886
Value change
-$4,336,824,619
Number of holders
2
Price from insider filings
$40.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AKERO THERAPEUTICS, INC. - Common Stock (AKRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GENERAL ATLANTIC, L.P. 8.4% $278,656,049 6,796,489 General Atlantic, L.P. 31 Mar 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% $180,902,408 3,810,076 T. Rowe Price Associates, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 4.1% -48% $138,062,973 -$117,126,544 3,397,779 -46% JANUS HENDERSON GROUP PLC 31 Dec 2025

As of 31 Dec 2025, 2 institutional investors reported holding 20,018 shares of AKERO THERAPEUTICS, INC. - Common Stock (AKRO). This represents 0.02% of the company’s total 82,872,659 outstanding shares.

Institutional Holders of AKERO THERAPEUTICS, INC. - Common Stock (AKRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 20,018 $532,984 -$4,336,824,619 $40.63 2
2025 Q3 91,447,334 $4,342,160,649 -$45,116,104 $47.48 260
2025 Q2 92,131,681 $4,916,497,064 +$352,115,121 $53.36 253
2025 Q1 86,154,634 $3,503,843,061 +$531,433,647 $40.48 238
2024 Q4 74,174,925 $2,063,406,098 -$8,506,883 $27.82 188
2024 Q3 73,002,070 $2,094,264,742 +$38,454,830 $28.69 167
2024 Q2 71,810,586 $1,684,723,283 -$32,810,693 $23.46 152
2024 Q1 73,087,900 $1,845,988,959 +$363,844,050 $25.26 171
2023 Q4 58,426,478 $1,364,286,476 -$103,406,827 $23.35 153
2023 Q3 56,757,185 $2,870,716,263 +$69,098,588 $50.58 178
2023 Q2 56,372,656 $2,631,606,875 +$394,199,729 $46.69 156
2023 Q1 48,070,649 $1,839,011,256 -$64,149,034 $38.26 155
2022 Q4 48,581,649 $2,661,931,733 +$138,143,044 $54.80 159
2022 Q3 46,589,695 $1,586,331,269 +$490,029,839 $34.05 142
2022 Q2 34,862,359 $329,587,739 -$12,722,696 $9.45 107
2022 Q1 35,141,546 $498,682,069 -$2,941,499 $14.19 98
2021 Q4 35,317,227 $746,760,550 +$3,654,957 $21.15 96
2021 Q3 27,981,387 $625,678,377 +$7,096,019 $22.35 102
2021 Q2 27,584,397 $684,200,429 -$121,336,833 $24.81 94
2021 Q1 31,507,544 $913,643,371 +$20,106,775 $29.01 109
2020 Q4 30,844,129 $813,955,792 +$45,233,337 $25.80 94
2020 Q3 28,988,756 $892,491,434 +$220,301,852 $30.79 103
2020 Q2 21,827,155 $543,916,299 -$2,246,835 $24.92 75
2020 Q1 22,025,386 $466,923,796 +$63,234,074 $21.20 66
2019 Q4 19,000,379 $421,605,474 +$18,157,481 $22.19 57
2019 Q3 12,742,598 $288,264,741 +$54,821,814 $22.75 54
2019 Q2 10,674,595 $204,526,000 +$204,526,000 $19.15 48